I missed Misslings talk today, but here is some notes taken by a stocktwits poster:
"when the last AD patient finishes (which should be soon) they will announce it. Confirmed data 2h. Actually said Excellence said 2h (I think he’s being optimistic or they pushed the dates out further then they needed to avoid missing another deadline). Only 2 questions asked at the end. 1st one being on the timing of AD (see above :)) and the 2nd one being about the difference in our approach vs Abeta targeting drugs. He explained the upstream MOA and that we target not only Abeta, but Tau, inflammation, mitochondrial distinction and calcium regulation. Nothing earth shattering new, but extremely positive and Missling definitely continues to improve both in his confidence, speech,"
-------------------------------------------------------------------------------
I'm glad to hear that he will PR when the trial finishes with the last patient completing, that was good news to hear. Evidently he has got an ear full about his former lack of communicating details the shareholder should be made aware of..
Market Data 
Markets 
AI
